Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference
Reviva Pharmaceuticals (NASDAQ: RVPH) announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO, will participate in the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025 in New York City.
The conference will feature more than 60 selected companies, over 500 institutional and high-net-worth investors, main-stage presentations, expert panels, curated one-on-one meetings, and networking sessions designed to connect growth companies with the investment community.
Investors seeking registration or agenda details are directed to the Spartan Capital Investor Conference 2025 registration page.
Reviva Pharmaceuticals (NASDAQ: RVPH) ha annunciato che Laxminarayan Bhat, Ph.D., fondatore, presidente e amministratore delegato, parteciperà alla Spartan Capital Securities Second Annual Investor Conference il 3 novembre 2025 a New York.
La conferenza includerà oltre 60 aziende selezionate, oltre 500 investitori istituzionali e di alto patrimonio netto, presentazioni sul palco principale, panel di esperti, riunioni one-to-one curate e sessioni di networking progettate per mettere in contatto le aziende in crescita con la comunità degli investitori.
Gli investitori interessati a registrarsi o a dettagli sul programma sono invitati a consultare la pagina di registrazione della Spartan Capital Investor Conference 2025.
Reviva Pharmaceuticals (NASDAQ: RVPH) anunció que Laxminarayan Bhat, Ph.D., Fundador, Presidente y CEO, participará en la Spartan Capital Securities Second Annual Investor Conference el 3 de noviembre de 2025 en la ciudad de Nueva York.
La conferencia contará con más de 60 empresas seleccionadas, más de 500 inversores institucionales y de alto patrimonio, presentaciones en el escenario principal, paneles de expertos, reuniones uno a uno curadas y sesiones de networking diseñadas para conectar las empresas en crecimiento con la comunidad inversora.
Los inversores que buscan registrarse o detalles de la agenda deben dirigirse a la página de registro de Spartan Capital Investor Conference 2025.
Reviva Pharmaceuticals (NASDAQ: RVPH) 은(는) Laxminarayan Bhat, Ph.D., 창립자, 사장 및 최고경영자로서 Spartan Capital Securities Second Annual Investor Conference에 2025년 11월 3일 뉴욕시에서 참석한다고 발표했습니다.
이번 컨퍼런스에는 60개가 넘는 선발된 기업들, 500명 이상의 기관 및 고순자산 투자자, 본 무대 프레젠테이션, 전문가 패널, 큐레이션된 일대일 미팅, 투자 커뮤니티와의 연결을 목표로 하는 네트워킹 세션이 있을 예정입니다.
등록 또는 의제 세부 정보를 찾는 투자자들은 Spartan Capital Investor Conference 2025 등록 페이지를 확인하시기 바랍니다.
Reviva Pharmaceuticals (NASDAQ: RVPH) a annoncé que Laxminarayan Bhat, Ph.D., fondateur, président et PDG, participera à la Spartan Capital Securities Second Annual Investor Conference le 3 novembre 2025 à New York.
La conférence réunira plus de 60 entreprises sélectionnées, plus de 500 investisseurs institutionnels et fortunés, des présentations sur scène principale, des panels d'experts, des réunions en tête-à-tête organisées et des sessions de networking conçues pour connecter les entreprises en croissance avec la communauté d'investissement.
Les investisseurs souhaitant obtenir des informations sur l'inscription ou l'agenda sont invités à consulter la page d'inscription Spartan Capital Investor Conference 2025.
Reviva Pharmaceuticals (NASDAQ: RVPH) gab bekannt, dass Laxminarayan Bhat, Ph.D., Gründer, Präsident und CEO, am Spartan Capital Securities Second Annual Investor Conference am 3. November 2025 in New York City teilnehmen wird.
Die Konferenz wird mehr als 60 ausgewählte Unternehmen präsentieren, über 500 institutionelle und vermögende Investoren, Hauptbühnenpräsentationen, Fachpanels, kuratierte One-on-One-Meetings und Networking-Sessions bieten, die darauf abzielen, Wachstumsunternehmen mit der Investment-Community zu verbinden.
Investoren, die Registrierungs- oder Programm-Details suchen, werden gebeten, die Registrierungsseite der Spartan Capital Investor Conference 2025 zu konsultieren.
Reviva Pharmaceuticals (NASDAQ: RVPH) أعلن أن لكسمنارياان بات، دكتوراه، المؤسس، رئيس مجلس الإدارة والمدير التنفيذي، سيشارك في Spartan Capital Securities Second Annual Investor Conference يوم 3 نوفمبر 2025 في مدينة نيويورك.
ستضم المؤتمر أكثر من 60 شركة مختارة، وأكثر من 500 مستثمر مؤسسي وباهتمام من ذوي الثروات العالية، عروض رئيسية، لجان خبراء، لقاءات فردية مُنَسقة، وجلسات تواصل تهدف إلى ربط الشركات النامية بمجتمع الاستثمار.
يُطلب من المستثمرين الذين يبحثون عن تسجيل أو تفاصيل الجدول الرجوع إلى صفحة تسجيل Spartan Capital Investor Conference 2025.
Reviva Pharmaceuticals (NASDAQ: RVPH) 宣布，创始人、董事长兼首席执行官 Laxminarayan Bhat 博士将参加 Spartan Capital Securities Second Annual Investor Conference，于 2025年11月3日 在纽约市举行。
本次会议将汇集超过 60 家精选公司，超过 500 名机构及高净值投资者，主舞台演讲、专家小组、精心策划的一对一定向会谈以及旨在将成长型公司与投资界联系起来的社交环节。
寻找注册或日程详情的投资者请访问 Spartan Capital Investor Conference 2025 的注册页面。
- None.
- None.
CUPERTINO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, in New York City.
The conference will showcase more than 60 carefully selected companies across technology, healthcare, consumer, mining, precious metals, and other high-growth sectors. Over 500 institutional and high-net-worth investors are expected to attend. The event will feature main-stage presentations, expert panels, curated one-on-one meetings, and extensive networking sessions, creating meaningful opportunities for dialogue between growth companies and the investment community.
For more information about the conference and registration details, please visit Spartan Capital Investor Conference 2025 Registration.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
When will Reviva (RVPH) present at the Spartan Capital investor conference?
Who will represent Reviva (RVPH) at the November 3, 2025 conference?
What can investors expect from Reviva's (RVPH) appearance at the Spartan Capital conference?
How many investors and companies will attend the Spartan Capital Securities Second Annual Investor Conference?
Where can investors register to attend the Spartan Capital investor conference for Reviva (RVPH)?
